Novo Nordisk A/S supports secondary use of data from Novo Nordisk Sponsored clinical studies for conducting further legitimate scientific research as set out in the joint EFPIA-PhRMA Principles for Responsible Clinical Trial Data Sharing.
If you are a researcher, you can request access to anonymized patient level data and study protocols from studies which have been completed after 2001, if product indications have obtained marketing authorization in both the EU and US.
You can as data requestor submit a scientific research proposal to document the legitimacy of your research project and the qualifications of your research team.
Access to individual study participant level data can be considered if the data can be sufficiently anonymized to protect personal identifiable information, safeguarding study participants’ privacy, if patients’ informed consent which was given in relation to their participation in the clinical study, can be respected.
Novo Nordisk A/S current data sharing platform will be decommissioned by the end of 2024, and we are investigating alternative data sharing methods on high priority. More information about this will be disclosed on this website when we have news to share. If you need further information, please contact us using our mailbox irb-secretariat@novonordisk.com .